Pharmaceutical products, namely, pharmaceutical preparations for the treatment of neurological diseases and disorders

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of neurological diseases and disorders

Medical apparatus and instruments, namely, injectors without needles comprised of an intradermic, subcutaneous and/or intramuscular injection system; syringes for medical purposes

The mark consists of the combination of the terms "RUZEPTA METHOTREXATE" in stylized characters. The letters "Z","E","P" are in gray while "RU" and "TA" appear in black. The term "METHOTREXATE" is in small green letters. At the top right there is a blue sphere in a white circle, itself depicted in a green circle. The rest of the white in the mark is background only and is not being claimed as a feature of the mark.

The mark consists of in part the wording "OPYZEP" in upper-case stylized font and "NALOXONE" in lower-case stylized font. The letters "OPY" are black and the letters "ZEP" are gray. The word "NALOXONE" is yellow. The mark also includes a design element in the upper right corner comprised of an orange circle. Inside the circle is a red cross outlined in white. A yellow and white leaf appears in the center of the red cross.

The mark consists of the stylized word "RELZEPTIS" in which "REL" and "TIS" appears in black font and "ZEP" appears in grey font above the stylized green word "METHOTREXATE" with a green circle with a blue circle with a light mark at the top of the circle inside it to the upper right of the word "RELZEPTIS". The mark appears on a white background which is not claimed as a feature of the mark.

The mark consists of the word "CROSSJECT" in blue with a blue curved line above the lettering "JECT" and a blue curved line below the lettering "CROSS", and the curved blue lines appearing darker blue near the letters "C" and "T" and each lighter near the second letter "S

Pharmaceuticals preparations, namely, pharmaceutical preparations containing hydrocortisone for endocrinological disorders

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of polyarthritis and autoimmune diseases

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of polyarthritis and autoimmune diseases

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of polyarthritis and autoimmune diseases